1. Introduction {#s0005}
===============

Cystic Fibrosis (CF) is an autosomal recessively inherited disease most prevalent in Caucasian populations of European origin ([@bb0005]). In the UK about 10,000 people have CF, globally about 70--100,000 people are affected ([@bb0005]). Although CF is a multisystem condition the majority of CF associated morbidity and mortality is a consequence of chronic suppurative lung disease and ultimately respiratory failure ([@bb0010], [@bb0020]), currently median (95% CI) age of death in the UK is 29 (27--31) ([@bb0010]). Infection of the lower airways by *Pseudomonas* ([@bb0025]), and *Burkholderia* species ([@bb0030], [@bb0035]) adversely affects morbidity, quality of life and survival, and there are increasing concerns about the consequences of infection with emergent ([@bb0040]) pathogen species such as *Mycobacterium abscessus* ([@bb0045], [@bb0050]). In CF, *Pseudomonas* ([@bb0025]) and *Burkholderia* ([@bb0030], [@bb0035]) species grow in biofilms and as such are much more resistant to antibiotics compared with planktonic-growing cells of the same isolate ([@bb0055]). The aggressive use of antibiotics to suppress chronic infection and to treat acute exacerbations has contributed to the increased survival of people with CF. However, increasing antibiotic resistance, multiple antibiotic resistance and drug intolerance are emerging as major clinical problems. These issues have led to calls for research into new antimicrobial agents and new antibiotic strategies to target the biofilm and to increase the effectiveness of currently available antibiotics ([@bb0060]).

We have previously described the *in vitro* antimicrobial, anti-biofilm and mucoactive properties of cysteamine as a monotherapy and in combination with CF guideline recommended antibiotics ([@bb0065]). Cysteamine has been routinely used to treat cystinosis for more than 20 years and so a significant body of clinical data already exists as to its characteristics within this patient group. The antimicrobial and mucoactive attributes of cysteamine described to date are potentially therapeutically beneficial in CF, not only in the treatment of acute exacerbations but also chronic management ([@bb0065]). An inherent limitation of the data derived thus far is that they were generated from monocultures of bacteria most commonly isolated from people with CF and against individual components of mucus. To investigate the potential of cysteamine in CF under more physiologically robust conditions, we investigated its mucolytic and antimicrobial activity against sputum from CF patients and report here for the first time on its rheological properties and antimicrobial action against the polymicrobial content of CF sputum. We also report on the activity of cysteamine against *M. abscessus* isolates from CF participants in this study.

2. Methods and Materials {#s0010}
========================

2.1. Subjects {#s0025}
-------------

Patients attending the adult CF clinic at Aberdeen Royal Infirmary, Aberdeen, UK were invited to participate in a cross-sectional study investigating the antimicrobial properties of cysteamine in sputum from people with CF. The inclusion criteria were: diagnosed CF associated lung disease and able to spontaneously expectorate sputum; 57 patients fulfilled the eligibility criteria and were invited to participate. Participants provided a sample of spontaneously expectorated sputum. The clinical data collected included: age, sex, height, weight, ventilatory function (FEV~1~) and CF genotype. Also recorded were the bacterial species infecting the sputum ([@bb0070]) and whether the participant was exacerbating, had a recent exacerbation (completed treatment \< 4 weeks previously) or was clinically stable (exacerbation \> 4 weeks previously). Antimicrobial therapy at the time of sampling was recorded *e.g.* azithromycin, inhaled therapies. The study received ethical approval (13/NS/0001) from the North of Scotland Research Ethics Service and all participants provided written informed consent.

2.2. Chemicals and Growth Media {#s0030}
-------------------------------

Tobramycin was purchased from Discovery Fine Chemicals (UK). All other chemicals, growth media and antibiotics were obtained from Sigma-Aldrich (UK).

2.3. Effect of Cysteamine and Antibiotics on CF Sputum Microbial burden: Single Exposure {#s0035}
----------------------------------------------------------------------------------------

Sputum samples were processed for antimicrobial activity within 4 h of collection. To assess the antimicrobial impact of cysteamine alone and cysteamine in conjunction with antibiotics commonly used to treat infective exacerbations of CF lung disease, 0 · 2 ml of each sputum sample sputum was diluted tenfold in sterile phosphate buffered saline (PBS) and vortexed. Aliquots (0 · 2 ml) of the homogenised diluted sample were exposed to cysteamine only (1 mg/ml) ([@bb0065]), antibiotic (tobramycin \[0 · 1 mg/ml\] or ciprofloxacin, \[0 · 1 mg/ml\] only), cysteamine plus antibiotic or vehicle (PBS) only, for 4 h and 24 h at 37 °C. Sputum samples were then serially diluted tenfold (1 × 10^− 1^ to 1 × 10^− 8^) and spread-plated on non-selective nutrient agar plates. Cultures were incubated at 37 °C and colony forming units per ml (cfu/ml) of bacteria quantified at 48 h.

2.4. Determination of CF Sputum Microbial Burden: Multiple Exposures {#s0040}
--------------------------------------------------------------------

To assess any impact of cysteamine on sputum microbial burden in CF at pharmacological concentrations reported *in vivo*, multiple dosing experiments were conducted. In these assays, 0 · 2 ml of sputum were exposed daily (first dosing within 4 h of collection as above) to 2 μg/ml of cysteamine, or PBS as a control, for 14 days. 2 μg/ml is a level typically reported when dosing with cysteamine in patients with cystinosis ([@bb0075]). On alternate days, 10 μl of each sample was recovered and serially diluted tenfold (1 × 10^− 1^ to 1 × 10^− 8^) and spread-plated on non-selective nutrient agar plates. Cultures were incubated at 37 °C and cfu/ml of bacteria quantified at 48 h.

2.5. Quantification of CF Sputum Macrorheological Properties (spinnbarkeit) {#s0045}
---------------------------------------------------------------------------

Macrorheological analysis was conducted within 4 h of collection of sputum samples. Aliquots (0 · 2 ml) of sputum were incubated for 1 h at 37 °C after the addition of cysteamine (1 mg/ml), PBS or DNAse (500 U/ml). The treated sputum samples were was then transferred to the open end of a 2 ml graduated pipette (Greiner, UK) which was secured vertically. Each sputum sample was allowed to descend inside the pipette under gravity. This process was timed and filmed, and the velocity of the sputum was calculated as distance travelled over time taken in mm/s.

2.6. Antimicrobial Susceptibility of *Mycobacteria Abscessus* Sputum Isolates *in vitro* {#s0050}
----------------------------------------------------------------------------------------

*M. abscessus* complex (MAC) was isolated from three participating patients. The susceptibility of these isolates, plus the MAC type strain *M. abscessus* DSMZ44196 to the antimicrobial effects of cysteamine alone and to cysteamine combined with antibiotics employed in MAC eradication strategies (amikacin, azithromycin and meropenem) was assessed by CLSI broth microdilution procedure ([@bb0080]) and checkerboard assay respectively.

2.7. Statistical Considerations {#s0055}
-------------------------------

FEV~1~ was expressed as a percentage of predicted using GLI 2012 ([@bb0085]) reference equations. Sputum microbial load expressed as colony forming units approximated to a log-normal distribution and was therefore expressed as mean log~10~ (95% confidence interval). The microbial load of CF sputum samples after incubation with cysteamine, tobramycin, ciprofloxacin or combinations thereof after 4 h and 24 h was modelled using two way repeated measures ANOVA with post hoc testing using Bonferroni adjustment. Analyses were performed using IBM SPSS Statistics for Windows, v22 · 0 (Armonk, NY).

2.8. Role of the Funding Source {#s0060}
-------------------------------

This study was funded by Scottish Enterprise. The funder did not contribute to study design, data collection, analysis, this report or the decision to publish.

3. Results {#s0015}
==========

3.1. Patient Population {#s0065}
-----------------------

Twenty three of the eligible 57 patients participated in the study, each provided a sputum sample, their clinical characteristics are outlined in [Table 1](#t0005){ref-type="table"}. All of the 15 patients infected with *Pseudomonas aeruginosa* were infected by at least one mucoid strain.

3.2. Antimicrobial Activity of Cysteamine Against Polymicrobial Burden in CF Sputum {#s0070}
-----------------------------------------------------------------------------------

The antimicrobial activity of tobramycin, cysteamine and combined tobramycin/cysteamine were tested in all 23 samples and are presented in [Fig. 1](#f0005){ref-type="fig"}. Cysteamine reduced sputum polymicrobial load after 4 h in sputum samples from 20 patients and from 21 patients after 24 h. When compared with untreated samples tobramycin, cysteamine and combined cysteamine/tobramycin reduced polymicrobial load at 4 h and 24 h (all p \< 0.001). Overall, tobramycin, cysteamine and combined cysteamine/tobramycin significantly (p \< 0 · 001) reduced polymicrobial load by 1 · 42 (95% CI 0 · 92--1 · 92), 3 · 18 (95% CI 2 · 30--4 · 07), and 3 · 86 (95% CI 3 · 11--4 · 61) log~10~ units respectively. When compared with tobramycin, cysteamine further reduced polymicrobial load by 1 · 76 (95% CI 0 · 89--2 · 63, p \< 0 · 001) log~10~ units. When compared with tobramycin, at 4 h combined cysteamine/tobramycin reduced polymicrobial load by 1.03 (95% CI − 0 · 50--1 · 56, p = 0 · 001) log~10~ units above that observed with tobramycin. After 24 h of exposure cysteamine/tobramycin further reduced polymicrobial load by 3 · 75 (95% CI 2 · 63--5 · 07, p \< 0 · 001) log~10~ units above that seen with tobramycin (5.65, 95% CI 4.46--6.80).

There was sufficient sputum to test antimicrobial activity of ciprofloxacin, cysteamine and combined ciprofloxacin/cysteamine in nine samples, the clinical characteristics of this subgroup are presented in [Table 1](#t0005){ref-type="table"} and the results are presented in [Fig. 2](#f0010){ref-type="fig"}. When compared with untreated samples cysteamine and combined cysteamine/ciprofloxacin reduced polymicrobial load at 4 h and 24 h (all p \< 0.005), ciprofloxacin reduced polymicrobial load at 24 h (p = 0.001) but not at 4 h (p = 0.234). Overall ciprofloxacin, cysteamine and combined cysteamine/ciprofloxacin significantly reduced polymicrobial load by 0 · 84 (95% CI 0 · 29--1 · 39, p = 0 · 008), 2 · 76 (95% CI 1 · 32--4 · 20, p = 0 · 002), and 2 · 86 (95% CI 1 · 68--3 · 98, p \< 0 · 001) log~10~ units respectively. When compared with ciprofloxacin, cysteamine further reduced polymicrobial load by 1 · 92 (95% CI 0 · 85--3 · 00, p = 0 · 003) log~10~ units. Overall when compared with ciprofloxacin combined cysteamine/ciprofloxacin further reduced polymicrobial load by 1 · 99 (95% CI 1 · 02--2 · 96, p \< 0 · 001) log~10~ units, however combined cysteamine/ciprofloxacin did not reduce polymicrobial load over and above that achieved by cysteamine alone.

Inclusion of clinical factors in the repeated measures ANOVA analysis demonstrated that sex, CF genotype, FEV~1~, exacerbation status, or concomitant use of azithromycin, inhaled antibiotics or ivacaftor did not modify the antimicrobial effects reported above.

3.3. Antimicrobial Activity of Cysteamine at a Pharmacological Concentration in CF Sputum {#s0075}
-----------------------------------------------------------------------------------------

The effects of *in vitro* daily dosing of sputum from 13 CF patients with 2 μg/ml cysteamine and PBS over a two week period are presented in [Fig. 4](#f0020){ref-type="fig"}, the clinical characteristics of this subgroup are presented in [Table 1](#t0005){ref-type="table"}. This dose of cysteamine is typical of the plasma levels observed in patients with cystinosis after dosing with cysteamine ([@bb0080]). Cysteamine significantly reduced the polymicrobial burden in CF sputum (Greenhouse--Geisser corrected p = 0 · 032) from about day 10 onwards. Sputum microbial load after 10 days of treatment was lower with cysteamine but this was only significant for day 10 (p = 0 · 044) but not day 14 (p = 0 · 088).

3.4. Sputum Macrorheology/spinnbarkeit {#s0080}
--------------------------------------

The effect of cysteamine on sputum spinnbarkeit was tested in samples from six participants where the volume of sputum provided permitted analysis, the clinical characteristics of this subgroup are presented in [Table 1](#t0005){ref-type="table"}. Cysteamine was a potent mucolytic in all CF sputum samples tested, outperforming human recombinant DNAse I (p = 0 · 016), a widely used mucolytic in the CF-field ([@bb0090]), in its reduction of sputum viscoelasticity after 1 h treatment at 37 °C ([Fig. 3](#f0015){ref-type="fig"}). The effect on sputum spinnbarkeit after 1 h is demonstrated in the [Video clip Fig. 5](#ec0005){ref-type="supplementary-material"}, but improvements in sputum viscosity treated with cysteamine were rapid and noticeable even after 5 min (data not shown).

3.5. Antimicrobial Susceptibility of *Mycobacterium Abscessus* Sputum Isolates *in vitro* {#s0085}
-----------------------------------------------------------------------------------------

The *M. abscessus* isolated from three of the study subjects (in whose sputum samples a significant reduction in polymicrobial burden was brought about with exposure to cysteamine and cysteamine plus tobramycin or ciprofloxacin) were all sensitive to the antimicrobial effects of cysteamine (MIC range 62 · 5--250 μg/ml) when tested *in vitro*, as was the type strain DSMZ44196 ([Table 2](#t0010){ref-type="table"}). Furthermore, cysteamine potentiated the impact of amikacin in both clinical and type strains, and azithromycin in all but one clinical strain, with fractional inhibitory concentration indices (FICI) ([@bb0095], [@bb0100]) demonstrating the more than additive or synergistic potential of combined therapy. Cysteamine had concentration-dependent effects on meropenem sensitivity in the clinical isolates and type strain of *M. abscessus* tested, showing some concentration-specific antagonism.

4. Discussion {#s0020}
=============

Cysteamine is an aminothiol (HSCH~2~CH~2~NH~2~) endogenously present at very low levels as a consequence of coenzyme A metabolism ([@bb0105], [@bb0110]). In the US and EU, cysteamine has been licensed for the treatment of nephropathic cystinosis for over 20 years. In this observational study the *in vitro* antimicrobial and mucoactive properties of cysteamine were tested in sputum samples from adults with CF infected with bacteria typical of those reported in the UK CF population (*Staphylococcus aureus*, *P. aeruginosa*, *Burkholderia* species and *Stenotrophomonas maltophilia*). Cysteamine reduced sputum polymicrobial load *ex vivo* and at the doses tested this antimicrobial effect was greater than that observed for tobramycin and ciprofloxacin. The combination of cysteamine with tobramycin appeared to be more than additive after 24 h incubation, being greater than the individual effects of cysteamine or tobramycin. The combination of cysteamine/ciprofloxacin appeared to be no more antimicrobial than cysteamine alone, although we have previously demonstrated a synergistic interaction for these two compounds *in vitro* ([@bb0065]). Whilst the lack of synergy between cysteamine and ciprofloxacin may merely be a consequence of the small number of sputum samples analysed (n = 9), it may be that in the matrix of sputum the combination of cysteamine/ciprofloxacin is unable to exert the additive effect present when cultured under standard media conditions, further work is required to investigate whether *in vivo* there is synergy between cysteamine and ciprofloxacin. In our present study, we also demonstrated that *M. abscessus* is sensitive to cysteamine; more so than for other CF bacteria when tested *in vitro* as a monotherapy. Cysteamine also potentiates the activity of other antimicrobial agents. In addition to cysteamine\'s antimicrobial effects, *in vitro*, cysteamine had mucolytic effects, reducing sputum viscosity 8--9 fold, notably cysteamine had more potent (6--7 fold) mucolytic effect than recombinant DNAse. We demonstrated that the antimicrobial effects of cysteamine were not modified by clinical factors *e.g.* sex, lung function, exacerbation status nor by concurrent medication *e.g.* azithromycin, inhaled antibiotics or ivacaftor. However, these analyses were of small numbers of patients and lacked statistical power, further work is required to determine whether any antimicrobial effects of cysteamine are modified by concurrent medications, or other factors *e.g.* disease severity, sex, age.

Previous *in vitro* studies using type strains and monocultures of bacterial pathogens have shown cysteamine to have direct antimicrobial activity with MIC~100~ at concentrations in the range of 250--500 μg/ml (in nutrient rich media) against *P. aeruginosa* and other CF pathogens including *Burkholderia cepacia* complex, *S. aureus* and also emerging pathogens including *Achromobacter xylosoxidans*, and *Stenotrophomonas* species ([@bb0065]). The current study is a more clinically relevant investigation because cysteamine was exposed to polymicrobial populations of CF-associated pathogens in their natural clinical matrix *i.e.* sputum from patients with CF. The data derived are a progression from, and concur with previous observed *in vitro* antimicrobial and mucolytic effects.

The present study demonstrates that cysteamine is antimicrobial and mucoactive within CF sputum. It has also been shown that cysteamine rescues the functional expression of the F508del CF transmembrane conductance regulator (CFTR) in CFTR F508del homozygous mice. In a study of 10 F508del homozygous patients with CF aged 8--25 years the sequential administration of oral cysteamine and the green tea flavonoid epigallocatechin gallate (EGCG) improved CFTR function, decreased sweat chloride concentrations and reduced sputum TNF and CXCL8 protein levels ([@bb0115]). In the present study, the effects of cysteamine are independent of CFTR genotype, suggesting that future trials of cysteamine as an antimicrobial-mucolytic should not be limited to F508del homozygous patients with CF. Thiols such as cysteamine and N-acetylcysteine have many biological properties, the mucolytic effects of cysteamine are likely to be a consequence of the thiol moiety reducing disulphide bonds in mucus proteins, disrupting their ligand bonding and structure ([@bb0120]). N-acetylcysteine has also been shown to have antimicrobial and antibiofilm activity and synergy with ciprofloxacin against *P. aeruginosa* has been inconsistently reported ([@bb0125]). The antibiofilm activity of N-acetylcysteine has been attributed to thiol disruption of disulphide bonds in enzymes involved in biofilm synthesis, it is possible that similar effects on proteins involved in gene expression, signalling and cell cycling underlie the antimicrobial effects of cysteamine.

The doses of cysteamine applied for the single exposure experiments in the present study were four times the median MIC~100~ previously established for cysteamine against CF associated pathogens in nutrient-rich media ([@bb0065]). Presently we do not know what, if any, local levels of cysteamine may be achievable in the sputum of CF patients after oral or aerosol delivery. It is known however, that in patients with cystinosis, after a single standard dose of cysteamine at steady state, peak plasma concentration is 2--3 μg/ml ([@bb0075]). In an attempt to evaluate *ex vivo* the effects of cysteamine at these much lower concentrations, sputum samples were exposed daily to 2 μg/ml cysteamine for 14 days. The data from these experiments suggest that significant reductions in total microbial sputum burden are likely to be achieved if cysteamine were to be used as an adjunct to conventional antimicrobial therapy for the typical 14 day course used to treat acute infective exacerbations of CF lung disease. Consideration of the physical properties of cysteamine predict that *in vivo* the antimicrobial effect of 14 days oral cysteamine is likely to be greater than that observed in the current study. With an acid dissociation constant (pKa) of 10.4, and a partition coefficient (logP) of 0.01 ([@bb0130]), cysteamine is likely to pass from the systemic circulation into the acidic bronchial secretions (pH 6.0--6.9) ([@bb0135]) such that the concentration of cysteamine will be higher in the bronchial secretions than in the systemic circulation.

A key consideration when developing any potential new antimicrobial strategy, particularly one based on a broad-spectrum agent, is its impact on resistance and whether modifying the existing microbiome creates niches for additional, emerging pathogens. It will be very difficult to establish until introduction into clinical practice whether this is the case for cysteamine, but there is now *in vitro* and *ex vivo* evidence that cysteamine is active against emerging pathogens. We have already reported antimicrobial activity against species such as *Achromobacter* species and *Stenotrophomonas* species ([@bb0065]) and in the current study we have furthered this work by investigating whether cysteamine has antimicrobial activity against the emerging pathogen *M. abscessus*. The prevalence of *M abscessus* infection in patients with CF is increasing and there is great clinical concern since this microorganism is multidrug resistant and patient to patient transmission has been recently demonstrated ([@bb0140]). Three of the participants in this study were infected with *M. abscessus* and their isolates were all clearly sensitive to cysteamine when tested *in vitro*, not only as a monotherapy but particularly in combination with amikacin and azithromycin. Although the strains tested were already sensitive to amikacin as defined by CLSI breakpoints, this sensitivity increased markedly in each of the strains tested. The same was true for the *M. abscessus* type strain. Indeed the MIC~100~ for cysteamine against *M. abscessus* was lower than we previously reported for *Pseudomonas* species and all other CF pathogens. The identification of an orally active agent against *M. abscessus* could be potentially useful, the synergism between cysteamine and amikacin and azithromycin could be advantageous in the protracted continuation phase of *M. abscessus* therapy, however the dose-dependent antagonism of meropenem may preclude the use of cysteamine in the initial intensive phase of treatment. Although this study has identified a potentially useful drug for the treatment of patients with CF infected with *M. abscessus*, only four isolates were tested in an extracellular *in vitro* context so further work is clearly required.

The study we report here further supports continued development of cysteamine as a novel "re-purposed" candidate CF treatment by confirming activity and therapeutic potential in the biological matrix (CF sputum) and raises the prospect of cysteamine being used to treat *M. abscessus*. It remains to be confirmed however, the extent to which oral cysteamine is absorbed and enters the bronchial secretions of patients with CF. The tolerability of cysteamine when used in patients with CF also needs to be ascertained because chronic oral cysteamine therapy (in cystinosis) is associated with side-effects that could be detrimental to the overall long term health of patients with CF, *e.g.* anorexia, nausea, breath odour, lethargy, osteopenia and skin striae. These side effects may not preclude the use of oral cysteamine as an adjunct to conventional antimicrobial treatment of acute infective exacerbations of CF lung disease. They could however, be problematic long term, but overcome by the development of an inhaled form of cysteamine for chronic dosing.

The following is the supplementary data related to this article.Video clip Fig. 5Comparative effects of DNAse I and cysteamine treatment (for 1 h at 37 °C) on the spinnbarkeit of sputum taken from a volunteer with cystic fibrosis.

Supplementary data to this article can be found online at [http://dx.doi.org/10.1016/j.ebiom.2015.08.018](10.1016/j.ebiom.2015.08.018){#ir0015}.
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###### 

Clinical characteristics of participating patients.

                                    All subjects (n = 23)   Ciprofloxacin subgroup (n = 9)   Low dosing subgroup (n = 13)   Rheology subgroup (n = 6)
  --------------------------------- ----------------------- -------------------------------- ------------------------------ ---------------------------
  Age (yrs) (median, IQR)           28 (19--36)             24 (19--37)                      29 (19--36)                    24 (19--45)
  Female (n,%)                      13 (57%)                6 (67%)                          6 (46%)                        
  DF508homozygous (n,%)             16 (70%)                8 (89%)                          9 (69%)                        5 (83%)
  DF508heterozygous                 6 (26%)                 1 (11%)                          3 (23%)                        1 (17%)
  DF508 negative                    1 (4%)                  0                                1 (8%)                         0
  BMI (mean 95% CI)                 22.1                    22.0                             22.4                           22.3
                                    (20.9--23.3)            (19.1--24.9)                     (20.5--24.4)                   (17.6--27.0)
  FEV~1~% predicted (mean 95% CI)   62% (49--74)            54% (37--70)                     69 (52--85)                    53% (29--77)
  Last exacerbation (n,%)                                                                                                   
   Acute                            9 (39%)                 5 (56%)                          5 (39%)                        3 (50%)
   \< 4 weeks                       8 (35%)                 3 (33%)                          6 (46%)                        2 (33%)
   \> 4 weeks                       6 (26%)                 1 (11%)                          2 (15%)                        1 (17%)
  Concomitant medication                                                                                                    
   Azithromycin (n,%)               20 (87%)                9 (100%)                         11 (85%)                       6 (100%)
   Inhaled antibiotic (n,%)         20 (87%)                8 (89%)                          12 (92%)                       5 (83%)
   Ivacaftor (n,%)                  2 (9%)                  0                                0                              0
  Sputum culture (n,%)                                                                                                      
  *Staphylococcus aureus*           4 (17%)                 1 (11%)                          3 (23%)                        1 (17%)
  *Pseudomonas aeruginosa*          15 (65%)                6 (67%)                          8 (62%)                        5 (83%)
  *Burkholderia* species            4 (17%)                 2 (22%)                          2 (15%)                        0
  *Stenotrophomonas maltophilia*    2 (9%)                  1 (11%)                          2 (15%)                        1 (17%)
  *Mycobacterium abscessus*         3 (13%)                 0                                0                              0

###### 

Cysteamine activity against a panel of *M. abscessus* strains, synergy with the clinically relevant antibiotics, amikacin and azithromycin is demonstrated by chequerboard experiments and calculation of fractional inhibitory concentration index (FICI).

                         MIC~100~                                                                                                                                                                                                                 
  ---------------------- ------------- -------- ------ ------ -------------------------------------- ---------------------- ------------------------------------------------------- ---------- -------------------------------------------------- ---------
  DSM44196 (type)        62 · 5--125   64       4--8   1--2   32--64/62 · 5 (**1** · **5**--**2**)   Neutral                1--4/15 · 625--62 · 5 (**0** · **5**--**0** · **75**)   Additive   0 · 25/15 · 625 (**0** · **25**--**0** · **5**)    Synergy
  MR313292 (clinical)    125--250      16--64   4      8      32--64/250 (**2**--**2** · **5**)      Neutral-antagonistic   \< 1/\< 15 · 125--31 · 25 (**0** · **375**)             Synergy    4--8/250 (**1** · **25**--**2**)                   Neutral
  MR27419N (clinical)    125           64       16     1      64/125 (**2**)                         Neutral                4/62 · 5 (**0** · **75**)                               Additive   0 · 25/\< 15 · 625 (**0** · **375**)               Synergy
  MR313367D (clinical)   62 · 5--125   16--64   16     1      64/125 (**2**--**5**)                  Neutral-antagonistic   4/15 · 625--31 · 25 (**0** · **5**)                     Synergy    0 · 25/15 · 625 (**0** · **375**--**0** · **5**)   Synergy

All results are presented represent the mean of triplicate samples from experiments conducted three times.

Values shown in the table are MIC~100~. Where  antibiotics have been used in combination, the unhighlighted figures show the MIC~100~ range for each antibiotic, and the figures highlighted in bold are the fractional inhibitory concentration index (FICI) range. Values ≤ 0.5 are interpreted as synergy.
